Charpiat B, Bleyzac N, Tod M. Proton pump inhibitors are risk factors for viral infections: even for COVID-19? Clin Drug Investig. 2020;40:897–9.
Prag C, Prag M, Fredlund H. Proton pump inhibitors as a risk factor for norovirus infection. Epidemiol Infect. 2017;145:1617–23.
Vilcu A-M, Sabatte L, Blanchon T, Souty C, Maravic M, Lemaitre M, et al. Association between acute gastroenteritis and continuous use of proton pump inhibitors during winter periods of highest circulation of enteric viruses. JAMA Netw Open. 2019;2:e1916205.
Fisher L, Fisher A. Acid-suppressive therapy and risk of infections: pros and cons. Clin Drug Investig. 2017;37:587–624.
Sultan N, Nazareno J, Gregor J. Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials. Can J Gastroenterol. 2008;22:761–6.
Filion KB, Chateau D, Targownik LE, Gershon A, Durand M, Tamim H, et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut. 2014;63:552–8.
Yu L-Y, Sun L-N, Zhang X-H, Li Y-Q, Yu L, Yuan Z-Q-Y, et al. A review of the novel application and potential adverse effects of proton pump inhibitors. Adv Ther. 2017;34:1070–86.
Sachs G, Shin JM, Munson K, Scott DR. Gastric acid-dependent diseases: a twentieth-century revolution. Dig Dis Sci. 2014;59:1358–69.
Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat RevDrug Discov. 2003;2:132–9.
Lundell L. The physiological background behind and course of development of the first proton pump inhibitor. Scand J Gastroenterol. 2015;50:680–4.
Aguilera-Castro L, Martín-de-Argila-de-Prados C, Albillos-Martínez A. Consideraciones prácticas en el manejo de los inhibidores de la bomba de protone. Revista Española de Enfermedades Digestivas. Sociedad Española de Patología Digestiva/Arán Ediciones, S.L.; 2016;108:145–53.
Method of using (H+ /K+)ATPase inhibitors as antiviral agents - Patent US-5945425-A - PubChem. https://pubchem.ncbi.nlm.nih.gov/patent/US5945425. Accessed 1 Jan 2021.
Sasaki T, Yamaya M, Yasuda H, Inoue D, Yamada M, Kubo H, et al. The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells. Eur J Pharmacol. 2005;509:201–10.
Long J, Wright E, Molesti E, Temperton N, Barclay W. Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. F1000Res. 2015;4:30.
Homolak J, Kodvanj I. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19. Int J Antimicrob Agents. 2020;56:106044.
Brindley MA, Maury W. Endocytosis and a low-pH step are required for productive entry of equine infectious anemia virus. J Virol. 2005;79:14482–8.
Fredericksen BL, Wei BL, Yao J, Luo T, Garcia JV. Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus. J Virol. 2002;76:11440–6.
Blastland M, Freeman ALJ, van der Linden S, Marteau TM, Spiegelhalter D. Five rules for evidence communication. Nature. 2020;587:362–4.
Luxenburger H, Sturm L, Biever P, Rieg S, Duerschmied D, Schultheiss M, et al. Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID‐19: coincidence or underestimated risk factor? J Intern Med. 2020;289:121–4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361636/.
Lee SW, Ha EK, Yeniova AÖ, Moon SY, Kim SY, Koh HY, et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut. 2021;70:76–84.
Zhou J, Wang X, Lee S, Wu WKK, Cheung BMY, Zhang Q, et al. Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study. Gut. BMJ Publishing Group. 2020;0:1-2. https://gut.bmj.com/content/early/2020/12/08/gutjnl-2020-323668. Accessed 1 Jan 2021.
Almario CV, Chey WD, Spiegel BMR. Increased risk of COVID-19 Among Users of Proton Pump inhibitors. Am J Gastroenterol. 2020;115:1707–15.
Ramachandran P, Perisetti A, Gajendran M, Jean-Louis F, Bansal P, Dwivedi AK, et al. Pre-hospitalization proton pump inhibitor use and clinical outcomes in COVID-19. Eur J Gastroenterol Hepatol. 2020. [Published Ahead of Print]. Accessed 1 Jan 2021.
Hariyanto TI, Prasetya IB, Kurniawan A. Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infection. Digest Liver Dis. 2020;52:1410–2.
Kow CS, Hasan SS. Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID-19: a meta-analysis. J Intern Med. 2021;289:125–8.
Li G-F, An X-X, Yu Y, Jiao L-R, Canarutto D, Yu G, et al. Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis. Gut. 2020. [Published Online First]. Accessed 1 Jan 2021.
Roulet L. A nationwide cohort study with propensity score matching. Gut. BMJ Publishing Group; 2020. https://gut.bmj.com/content/early/2020/10/18/gutjnl-2020-323098. Accessed 1 Jan 2021.
Faillie J-L. Indication bias or protopathic bias? Br J Clin Pharmacol. 2015;80:779–80.
Wang C-H, Li C-H, Hsieh R, Fan C-Y, Hsu T-C, Chang W-C, et al. Proton pump inhibitors therapy and the risk of pneumonia: a systematic review and meta-analysis of randomized controlled trials and observational studies. Expert Opin Drug Saf. 2019;18:163–72.
Almario CV, Chey WD, Spiegel BMR. Increased risk of COVID-19 among users of proton pump inhibitors. 2020. https://pubpeer.com/publications/9317268820DED464956F15945D32AD?utm_source=Chrome&utm_medium=BrowserExtension&utm_campaign=Chrome. Accessed 1 Jan 2021.
Aby ES, Rodin H, Debes JD. Proton Pump Inhibitors and Mortality in Individuals With COVID-19. Am J Gastroenterol. 2020;115:1918.
Dahly D, Elia M, Johansen M. A letter of concern regarding increased risk of COVID-19 among users of proton pump inhibitors by Almario, Chey, and Spiegel. Zenodo. 2020. https://zenodo.org/record/3940578#.Xwn7meco-Uk. Accessed 1 Jan 2021.
Hajifathalian K, Katz PO. Regarding “Increased Risk of COVID-19 in patients taking proton pump inhibitors.” Am J Gastroenterol. 2020;115:1918–9.
Hadi YB, Naqvi SF, Kupec JT. Risk of COVID-19 in patients taking proton pump inhibitors. Am J Gastroenterol. 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553029/. Accessed 1 Jan 2021.
Tarlow B, Gubatan J, Khan MA, Cholankeril G. Are proton pump inhibitors contributing to SARS-COV-2 infection? Am J Gastroenterol. 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505035/. Accessed 1 Jan 2021.
Taştemur Ş, Ataseven H. Is it possible to use proton pump inhibitors in COVID-19 treatment and prophylaxis? Med Hypotheses. 2020;143:110018.
Ray A, Sharma S, Sadasivam B. The Potential therapeutic role of proton pump inhibitors in COVID-19: hypotheses based on existing evidences. Drug Res (Stuttg). 2020;70:484–8.
Conrad KP. Might proton pump or sodium-hydrogen exchanger inhibitors be of value to ameliorate SARs-CoV-2 pathophysiology? Physiol Rep. 2021;8:e14649.